Compare Bristol-Myers Squibb Co (BMY) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Jumia Technologies AG - ADR — how do they compare? Bristol-Myers Squibb Co trades at $58.38 (market cap $116.30B), while Jumia Technologies AG - ADR trades at $6.87 (market cap $848.39M). The key difference: Bristol-Myers Squibb Co is far larger — about 137.1× Jumia Technologies AG - ADR's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals.
| BMY | JMIA | |
|---|---|---|
Market Cap | $116.30B | $848.39M |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $14.60 |
52-Week Low | $42.60 | $4.45 |
Enterprise Value | $152.24B | $795.49M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
JMIA trades at $6.71, down 4.28% today, amid bearish technical signals despite analyst optimism. The company shows improving fundamentals with revenue growth to $189M in 2025 and narrowing losses, targeting 2027 profitability. Recent Q1 2026 results beat GMV guidance with 39% revenue growth, though EPS missed expectations. Cash flow turned positive in 2024-2025 after years of negative net flows.
Outlook remains speculative with high execution risk despite 71% analyst buy ratings. The path to profitability depends on successful African market expansion and cost management. Key risks include persistent losses, competitive pressures, and macroeconomic challenges in operating markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
